Reuters logo
BRIEF-Immunovaccine net loss, comprehensive loss of $2.4 mln for quarter ended March 31
May 10, 2017 / 10:06 PM / 7 months ago

BRIEF-Immunovaccine net loss, comprehensive loss of $2.4 mln for quarter ended March 31

May 10 (Reuters) - Immunovaccine Inc:

* Immunovaccine announces financial results for quarter ended March 31, 2017

* Net loss and comprehensive loss of $2.4 million for quarter ended march 31, 2017, up $518,000

* At March 31, 2017, immunovaccine had cash and cash equivalents of $11.8 million versus $13.5 million at Dec 31, 2016 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below